Insider filing · MBX

Carl L Gordon bought $2.0M of MBX Biosciences (MBX)

Executed Feb 14 2025, disclosed Feb 19 2025, 5 days later.

Over the 21 trading sessions from the disclosed entry session (Feb 19 2025), the stock returned -22.4% (delay-adjusted); from the execution session (Feb 14 2025), -2.0%. Derived: entry at the session's open, exit at the close 20 sessions later.

CG Carl L Gordon Director profile →

Carl L Gordon (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in BlossomHill Therapeutics, Inc. Common Stock (BLSM). Across 2 priced purchase filings, the average 21-session return was +56.2% from execution and +52.9% from disclosure (delay-adjusted; derived). The largest single filing was $15.0M of SCTX (1,000,000 sh × $15.00, as filed), executed Jul 27.

MBX MBX MBX · 8 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→